<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39381449</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Erythroderma Following Pfizer-BioNTech COVID-19 Vaccination in a Patient With Atopic Dermatitis: A Case Report.</ArticleTitle><Pagination><StartPage>e68936</StartPage><MedlinePgn>e68936</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68936</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68936</ELocationID><Abstract><AbstractText>Cutaneous adverse reactions to mRNA COVID-19 vaccines in patients with preexisting dermatologic disease include bullous eruptions, pityriasis rubra pilaris, dermatomyositis, and granuloma annulare. Erythroderma is a rare but severe adverse reaction not previously seen. This case report describes the development of erythroderma in a 73-year-old male with a history of atopic dermatitis, with widespread erythema and scaling covering 95% of his body surface area, which developed sequentially after receiving each dose of the Pfizer-BioNTech (BNT162b2) COVID-19 vaccination. The patient's condition improved significantly with appropriate dermatologic treatment, including systemic and topical corticosteroids and dupilumab. Thus, it is imperative to recognize erythroderma as a potential side effect of the Pfizer-BioNTech COVID-19 vaccine, particularly in patients with preexisting dermatologic conditions. Early diagnosis and treatment are vital for managing this potentially life-threatening reaction and preventing severe complications.</AbstractText><CopyrightInformation>Copyright © 2024, Handal et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Handal</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Kawaiola Cael</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartos</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dermatology, Imperial Dermatology, Hollywood, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">covid-19 vaccine</Keyword><Keyword MajorTopicYN="N">exfoliative dermatitis</Keyword><Keyword MajorTopicYN="N">mrna vaccine</Keyword><Keyword MajorTopicYN="N">mrna-based vaccine</Keyword><Keyword MajorTopicYN="N">pfizer-biontech vaccine</Keyword><Keyword MajorTopicYN="N">vaccine adverse events</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381449</ArticleId><ArticleId IdType="pmc">PMC11461041</ArticleId><ArticleId IdType="doi">10.7759/cureus.68936</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The impact of COVID-19 vaccination on inflammatory skin disorders and other cutaneous diseases: a review of the published literature. Martora F, Battista T, Ruggiero A, Scalvenzi M, Villani A, Megna M, Potestio L. Viruses. 2023;15:1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10384785</ArticleId><ArticleId IdType="pubmed">37515110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. McMahon DE, Amerson E, Rosenbach M, et al. J Am Acad Dermatol. 2021;85:46–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024548</ArticleId><ArticleId IdType="pubmed">33838206</ArticleId></ArticleIdList></Reference><Reference><Citation>A practical approach to the diagnosis and treatment of adult erythroderma. Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. Actas Dermosifiliogr (Engl Ed) 2018;109:777–790.</Citation><ArticleIdList><ArticleId IdType="pubmed">30316452</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper-Kirksey K. Life-Threatening Rashes. Cham, Switzerland: Springer; 2018. Erythroderma; pp. 265–277.</Citation></Reference><Reference><Citation>Erythroderma: a retrospective study of 212 patients hospitalized in a tertiary center in Lower Silesia, Poland. Kliniec K, Snopkowska A, Łyko M, Jankowska-Konsur A. J Clin Med. 2024;13:645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10856417</ArticleId><ArticleId IdType="pubmed">38337339</ArticleId></ArticleIdList></Reference><Reference><Citation>Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Miyashiro D, Sanches JA. Sci Rep. 2020;10:9774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300014</ArticleId><ArticleId IdType="pubmed">32555205</ArticleId></ArticleIdList></Reference><Reference><Citation>Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis. Durmus O, Akdogan N, Karadag O, Gokoz O. Dermatol Ther. 2022;35:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111652</ArticleId><ArticleId IdType="pubmed">35133700</ArticleId></ArticleIdList></Reference><Reference><Citation>Erythrodermic psoriasis after COVID-19 vaccination. Trepanowski N, Coleman EL, Melson G, Brem CE, Lam CS. JAAD Case Rep. 2022;28:123–126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9364664</ArticleId><ArticleId IdType="pubmed">35966353</ArticleId></ArticleIdList></Reference><Reference><Citation>31047 erythrodermic psoriasis secondary to the COVID-19 Moderna vaccine. Pabón-Cartagena G, Pelet del Toro NM, Russo M. J Am Acad Dermatol. 2022;87:0.</Citation></Reference><Reference><Citation>Erythrodermic pityriasis rubra pilaris following COVID-19 vaccination. Abdelkader HA, Khedr H, El-Komy MH. Cutis. 2024;113:0–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">38820101</ArticleId></ArticleIdList></Reference><Reference><Citation>Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab. Saad M, Bose R. JAAD Case Rep. 2023;42:7–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10630754</ArticleId><ArticleId IdType="pubmed">37961078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine. Ajebo EM, Howard JD, Anand D, Davis LS. JAAD Case Rep. 2022;23:114–116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013576</ArticleId><ArticleId IdType="pubmed">35465138</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Sechi A, Pierobon E, Pezzolo E, et al. Clin Exp Dermatol. 2022;47:437–440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652785</ArticleId><ArticleId IdType="pubmed">34617317</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination. Gambichler T. J Eur Acad Dermatol Venereol. 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">36914972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>